LNSRLNSRHealthcare · Medical Devices

LNSR Stock Forecast: LENSAR, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$4.46
−3.88% on the day

The 3 Wall Street analysts covering LENSAR, Inc. hold a median 12-month price target of $11 — +146.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 58 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$57.0M
Ticker Nerd rank
58/ 100
Median analyst target
$11
Analysts covering
3
Revenue$16.5M+18.4% y/y
Operating income$2.1M
Net income$3.5M
Free cash flow−$162K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.8%
1M
−23.2%
YTD
−61.7%
1Y
−54.0%
From 52W high
−65.0%
From 52W low
0.0%
$4
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores LENSAR, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
58/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
93
Quality
85
Value
70
Issuance
63
Volatility
41
Revisions
33
Momentum
20
Accruals
14

Growth (93): Sales and profits are climbing, and climbing faster than before.

Accruals (14): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LNSR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LNSR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12$14Jan 26Apr 26Jul 26Oct 26LNSRHigh $13Median $11Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3
Buy
0
Hold
0
Sell
$9
Low
$11
Median
$13
High

The green dot is the last close — the median target sits +146.6% from it.

Recent analyst actionsNewest first

Of the 10 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
10 Nov 2026BTIGMaintainsBuy$10 → $9.00
28 Sept 2026LUCID CAPITAL MARKETSInitiatesBuy$11
20 Aug 2026BTIGMaintainsBuy$9.00 → $10
13 Aug 2026BTIGMaintainsBuy$7.00 → $9.00
18 Mar 2026BTIGUpgradeBuy$10
24 Mar 2025Lake StreetDowngradeHold—
28 Feb 2025Lake StreetMaintainsBuy—
19 Mar 2024Lake StreetInitiatesBuy—
22 Nov 2021BTIGInitiatesBuy—
24 Feb 2021SVB LeerinkInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LNSR.

Market Radar

This page is one stock. Monday covers all of them.

LNSR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LNSR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, LENSAR, Inc. returned −54.0% against +6.9% for the S&P 500, dividends included.

LNSR vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26LNSRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LNSR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−96.3%
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
10.1×

Cheaper than 73% of US stocks

Price / sales
0.9×

Cheaper than 68% of US stocks

Price / book
4.9×

Cheaper than 18% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
59.3%

Higher than 73% of US stocks

Operating margin
−33.3%

Higher than 20% of US stocks

Net margin
56.1%

Higher than 96% of US stocks

Returns & dividend
Return on equity
529.3%

Higher than 99% of US stocks

Return on assets
−18.2%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • LENSAR, Inc. has a market value of $57.0M and an enterprise value of $60.4M.

  • Revenue in the twelve months to 30 June 2026: $60.3M. The latest quarter grew 18.4% year on year.

  • Net income over the same four quarters: $34.7M, a 57.6% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.33.

  • Free cash flow in the twelve months to 30 June 2026: −$7.3M.

  • Shares outstanding: 12.3M.

  • Trailing P/E: 10.1×.

  • LENSAR, Inc. employs 150 people — $402K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

LNSR and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
LNSRLENSAR, Inc.$57.0M58
COCHEnvoy Medical, Inc.$51.9M57
HYPRHyperfine, Inc.$58.0M42
OMOutset Medical, Inc.$51.4M52
MBOTMicrobot Medical, Inc.$45.7M15
SERASera Prognostics, Inc.$70.9M39
ELUTElutia, Inc.$39.9M30

Take a look at LNSR’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own LENSAR, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about LNSR

What is the LNSR stock price forecast for 2026-2027?

The 3 Wall Street analysts covering LENSAR, Inc. have a median 12-month price target of $11, with estimates ranging from $9 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LNSR stock a buy right now?

Of the 3 analysts covering LENSAR, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LENSAR, Inc. 58 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LNSR?

As at 21 Nov 2026, LENSAR, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).

Will LNSR stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +146.6% from the last close, and Ticker Nerd's factor model ranks LENSAR, Inc. 58 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LNSR stock forecast for 2030?

No analyst covering LENSAR, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LNSR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $13 over the next 12 months.

How has LNSR stock performed over the past year?

LENSAR, Inc. returned -54.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does LENSAR, Inc. do?

LENSAR Inc. is a commercial-stage medical device company focused on advanced laser systems for cataract surgery and astigmatism management. Its current portfolio centers on the LENSAR Laser System and the ALLY Robotic Cataract Laser System, which combine imaging, planning, and laser-based treatment tools to support surgeons in refractive cataract procedures.

Company

About LENSAR, Inc.

LENSAR Inc. is a commercial-stage medical device company focused on advanced laser systems for cataract surgery and astigmatism management. Its current portfolio centers on the LENSAR Laser System and the ALLY Robotic Cataract Laser System, which combine imaging, planning, and laser-based treatment tools to support surgeons in refractive cataract procedures. The company’s systems are used to help manage key steps of surgery, including treatment planning, precision delivery, and workflow efficiency in clinical settings. LENSAR also provides related consumables, procedure licenses, training, installation, and maintenance services, making its offerings part of a broader surgical platform rather than standalone hardware. Headquartered in Orlando, Florida, LENSAR serves ophthalmic practices and surgical centers in the United States and international markets.

CEO Mr. Nicholas T. Curtis · 150 employees · United States · https://www.lensar.com